Pulse Biosciences, Inc (NASDAQ:PLSE – Get Free Report) reached a new 52-week high on Tuesday . The company traded as high as $51.00 and last traded at $50.1640, with a volume of 14790 shares. The stock had previously closed at $50.33.
Wall Street Analysts Forecast Growth
Several brokerages have commented on PLSE. Needham & Company LLC started coverage on Pulse Biosciences in a report on Monday, August 17th. They issued a “buy” rating and a $58.00 price objective on the stock. Mizuho set a $45.00 target price on Pulse Biosciences in a research note on Monday, August 10th. Oppenheimer reaffirmed an “outperform” rating on shares of Pulse Biosciences in a research note on Tuesday, July 28th. Wall Street Zen upgraded Pulse Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, Canaccord Genuity Group lifted their price target on shares of Pulse Biosciences from $32.00 to $43.00 and gave the company a “buy” rating in a research note on Monday, August 10th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $45.25.
Check Out Our Latest Stock Report on Pulse Biosciences
Pulse Biosciences Stock Down 1.0%
Pulse Biosciences (NASDAQ:PLSE – Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.07). Pulse Biosciences had a negative net margin of 6,755.78% and a negative return on equity of 94.42%. The company had revenue of $0.43 million during the quarter, compared to analysts’ expectations of $0.53 million. Research analysts forecast that Pulse Biosciences, Inc will post -1.29 EPS for the current fiscal year.
Insider Buying and Selling at Pulse Biosciences
In other news, COO Liane Rae Teplitsky acquired 1,036 shares of the company’s stock in a transaction that occurred on Wednesday, August 26th. The stock was purchased at an average price of $48.23 per share, with a total value of $49,966.28. Following the completion of the acquisition, the chief operating officer owned 1,036 shares of the company’s stock, valued at $49,966.28. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 74.00% of the company’s stock.
Hedge Funds Weigh In On Pulse Biosciences
Institutional investors have recently bought and sold shares of the company. BNP Paribas Financial Markets boosted its holdings in Pulse Biosciences by 63.6% in the 2nd quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock valued at $26,000 after purchasing an additional 680 shares during the last quarter. Osterweis Capital Management Inc. acquired a new stake in shares of Pulse Biosciences during the 2nd quarter worth approximately $28,000. Tower Research Capital LLC TRC increased its holdings in shares of Pulse Biosciences by 275.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock worth $44,000 after buying an additional 2,156 shares during the last quarter. Russell Investments Group Ltd. raised its position in shares of Pulse Biosciences by 13.8% during the 4th quarter. Russell Investments Group Ltd. now owns 5,106 shares of the company’s stock valued at $70,000 after buying an additional 619 shares during the period. Finally, The Manufacturers Life Insurance Company purchased a new stake in shares of Pulse Biosciences during the 2nd quarter valued at approximately $158,000. 76.95% of the stock is owned by hedge funds and other institutional investors.
Pulse Biosciences Company Profile
Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.
The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.
Featured Articles
- Five stocks we like better than Pulse Biosciences
- Palantir’s Sovereign AI Pitch Tests Microsoft’s Cloud-First AI Bet
- Salesforce Looks Overbought, But the Rally May Be Far From Over
- Radar Anomaly: Draganfly’s Options Surge Signals Strategy Shift
- Boarding Call: EHang Secures First-Mover Altitude
Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
